Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 3% Improvement Relative Risk Gianfrancesco et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 600 patients in multiple countries No significant difference in hospitalization Gianfrancesco et al., Annals of the Rheumatic Di.., doi:10.1136/annrheumdis-2020-217871 Favors HCQ Favors control
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco et al., Annals of the Rheumatic Diseases, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871
Gianfrancesco et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the.., Annals of the Rheumatic Diseases, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871
May 2020   Source   PDF  
  All Studies   Meta
Analysis of rheumatic disease patients showing no significant association between antimalarial therapy and hospitalisation, OR=0.94 [0.57-1.57], p=0.82 after adjustments. This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the baseline risk differences within systemic autoimmune patients.
risk of hospitalization, 3.3% lower, RR 0.97, p = 0.82, treatment 58 of 130 (44.6%), control 219 of 470 (46.6%), NNT 50, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gianfrancesco et al., 28 May 2020, retrospective, database analysis, multiple countries, peer-reviewed, 28 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Epidemiology Clinical science Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-­reported registry Milena Gianfrancesco,1 Kimme L Hyrich,2,3 Sarah Al-­Adely,2,3 Loreto Carmona,4 Maria I Danila,5 Laure Gossec ‍ ‍,6,7 Zara Izadi,1 Lindsay Jacobsohn,1 Patricia Katz,1 Saskia Lawson-­Tovey,3,8 Elsa F Mateus,9 Stephanie Rush,1 Gabriela Schmajuk,1 Julia Simard,10 Anja Strangfeld,11 Laura Trupin,1 Katherine D Wysham,12 Suleman Bhana,13 Wendy Costello,14 Rebecca Grainger,15 Jonathan S Hausmann,16,17 Jean W Liew,12 Emily Sirotich,18,19 Paul Sufka,20 Zachary S Wallace,17,21 Jinoos Yazdany,1 Pedro M Machado ‍ ‍,22,23,24 Philip C Robinson ‍ ‍,25,26 On behalf of the COVID-19 Global Rheumatology Alliance Handling editor Josef S Smolen ►► Additional material is published online only. To view, please visit the journal online (http://​dx.​doi.​org/​10.​1136/​ annrheumdis-​2020-​217871). For numbered affiliations see end of article. Correspondence to Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Herston, QLD 4029, Australia; ​philip.​robinson@​uq.​edu.​au MG and KLH contributed equally. JY, PMM and PCR contributed equally. Received 4 May 2020 Revised 10 May 2020 Accepted 11 May 2020 © Author(s) (or their employer(s)) 2020. No commercial re-­use. See rights and permissions. Published by BMJ. To cite: Gianfrancesco M, Hyrich KL, Al-­Adely S, et al. Ann Rheum Dis Epub ahead of print: [please include Day Month Year]. doi:10.1136/ annrheumdis-2020-217871 Abstract Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease. Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed. Results A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-­ adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-­modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-­steroidal anti-­ inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-­TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed. Conclusions We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-­TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation. Key messages What is already known about this subject? ►► Data regarding..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop